SEC Form 4 · accession 0001562180-18-001907
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gil J Van Lunsen
Director
Period of report
Apr 18, 2018
Accepted (ET)
Apr 18, 2018 · 4:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 18, 2018 | M | 5,500 | $3.51 | A | 24,797 | D | |
| Common Stock | Apr 18, 2018 | M | 16,000 | $3.87 | A | 40,797 | D | |
| Common StockF2 | Apr 18, 2018 | S | 21,500 | $15.19 | D | 19,297 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $3.51 | Apr 18, 2018 | M | 5,500 | D | — | Nov 4, 2020 | Common Stock | 5,500 | 0 | D |
| Stock Option (Right to Buy)F4 | $3.87 | Apr 18, 2018 | M | 16,000 | D | — | Oct 30, 2024 | Common Stock | 16,000 | 9,000 | D |
Explanation of responses
- F1These trades were made pursuant to a Rule 10b5-1 trading plan.
- F2The price reported for these shares is the weighted average sale price. Details of actual prices for shares sold are available from the Issuer upon request.
- F3Options vested in three equal annual installments commencing November 4, 2011 and ending November 4, 2013.
- F4Options vested on October 30, 2015.